Cardinal Health Inc CAH
We take great care to ensure that the data presented and summarized in this overview for CARDINAL HEALTH INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CAH
View all-
Black Rock Inc. New York, NY30.8MShares$3.61 Billion0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$3.6 Billion0.06% of portfolio
-
State Street Corp Boston, MA14.2MShares$1.66 Billion0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA5.75MShares$673 Million0.05% of portfolio
-
Morgan Stanley New York, NY4.95MShares$579 Million0.04% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.29MShares$502 Million1.13% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.08MShares$360 Million0.28% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.07MShares$359 Million0.47% of portfolio
-
Invesco Ltd. Atlanta, GA3.04MShares$356 Million0.07% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.94MShares$344 Million0.09% of portfolio
Latest Institutional Activity in CAH
Top Purchases
Top Sells
About CAH
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Insider Transactions at CAH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2024
|
Ola M Snow Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
355
-1.29%
|
$43,310
$122.24 P/Share
|
Dec 02
2024
|
Mary C. Scherer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-1.03%
|
$10,980
$122.24 P/Share
|
Dec 02
2024
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
676
-1.11%
|
$82,472
$122.24 P/Share
|
Dec 02
2024
|
Deborah Weitzman CEO, PSS Segment |
SELL
Payment of exercise price or tax liability
|
Direct |
632
-1.27%
|
$77,104
$122.24 P/Share
|
Nov 15
2024
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,186
-6.83%
|
$627,506
$121.29 P/Share
|
Nov 14
2024
|
Mary C. Scherer Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,504
-28.59%
|
$430,992
$123.55 P/Share
|
Nov 06
2024
|
Robert Azelby Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+36.44%
|
-
|
Nov 06
2024
|
Michelle Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+19.77%
|
-
|
Nov 06
2024
|
Patricia Hemingway Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+5.25%
|
-
|
Nov 06
2024
|
David C Evans Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+10.79%
|
-
|
Nov 06
2024
|
Sheri H. Edison Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+11.15%
|
-
|
Nov 06
2024
|
Gregory B Kenny Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,812
+4.31%
|
-
|
Nov 06
2024
|
Akhil Johri Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+7.35%
|
-
|
Nov 06
2024
|
Christine Mundkur Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+21.1%
|
-
|
Nov 06
2024
|
Nancy Killefer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,730
+6.12%
|
-
|
Aug 21
2024
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Open market or private sale
|
Direct |
16,573
-17.91%
|
$1,806,457
$109.39 P/Share
|
Aug 19
2024
|
Jason M. Hollar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
46,455
-19.03%
|
$5,063,595
$109.02 P/Share
|
Aug 19
2024
|
Michelle D. Greene Chief Information Officer |
SELL
Open market or private sale
|
Direct |
4,000
-17.21%
|
$432,000
$108.85 P/Share
|
Aug 19
2024
|
Aaron E Alt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,323
-5.93%
|
$250,884
$108.91 P/Share
|
Aug 19
2024
|
Stephen M Mason CEO, GMPD Segment |
SELL
Open market or private sale
|
Direct |
46,998
-27.06%
|
$5,122,782
$109.45 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 315K shares |
---|---|
Exercise of conversion of derivative security | 41.3K shares |
Payment of exercise price or tax liability | 127K shares |
---|---|
Open market or private sale | 202K shares |
Bona fide gift | 943 shares |